If you are near Boston on December 1st, it will be more than worth the trip to the Inaugural Huntington Disease Clinical Research Symposium, hosted by the Huntington Study Group. This meeting is the first of its kind, and means that research for Huntingon people is on center stage.
There will be an impressive and diverse set of speakers. And there will be information on clinical trials from those in planning stages to those which have completed phase III testing. There will also be information on care and treatments for Huntington families.
In their Words: Huntington Study Group Announcement
The Inaugural Huntington's Disease Clinical Research Symposium will take place at the conclusion of the annual meeting of the Huntington Study Group (HSG). The HSG is a non-profit group of physicians and other health care providers from medical centers in the U.S., Canada, Europe and Australia experienced in the care of Huntington patients and dedicated to clinical research of Huntington's disease. The Inaugural HD Clinical Research Symposium will include 2 keynote speakers, 6 platform speakers and poster presentations. The symposium will focus on patient-oriented clinical research in HD, including recent developments from basic science and translational research as they apply directly to human clinical research. The primary audience will include physicians, nurses, psychologists and lay individuals dedicated to the clinical care research in HD patients and their families. Attendees of this symposium will be updated on the latest ground-breaking clinical research that has direct application to finding therapeutic treatments for individual suffering from HD. This symposium is designed to meet the unmet therapeutic and clinical needs in the clinical evaluation care and treatment of patients and families affected by HD. Review of the current literature suggests that no specific guidelines for treating HD exist. In addition this symposium will highlight the latest advances from basic and translational research that can directly apply to either clinical and/or the development of novel clinical trials for patients with HD.